
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines is a biotech company that is expected to continue its strong financial performance with ongoing trials and upcoming milestones. With a potential downside of 21% and an upside of 37%, the company's positive results for its currently approved drugs, Brukinsa and Sonrotoclax, suggest further success with its pipeline of over 50 drugs. There is some debate about the effectiveness of BeOne's unique approach to treating solid tumors, but their stock is currently valued at $430/ADR and analysts are recommending a Market Outperform rating.
Bears say
BeOne Medicines is a global commercial-stage biotech firm that produces oncology therapeutics. However, their main product, Brukinsa, has limited revenue potential outside of China and faces tough competition from established players like AbbVie and AstraZeneca. While they have a deep pipeline, the majority of their drugs are in early stages of development, posing a high level of risk for investors. Additionally, their recent phase 3 trial for SHINE showed mixed results and a high rate of adverse events, adding further uncertainty to the future success of their products. Hence, a negative outlook is warranted for BeOne Medicines' stock due to limited revenue potential, stiff competition, and high risk associated with their pipeline.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares